Drug Trial Radar · NCT07923214
A Phase I Dose Escalation Study of CG-7321 Monotherapy or Combination Therapy in Advanced Solid Tumors
Last checked: Nov 20, 2026Latest source record: Nov 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
66
Planned (sponsor's estimate)
Start
Jul 2, 2024
Primary completion
Apr 2027
Study completion Dec 2027
Sponsor
- Lead sponsor
- Chengdu Cynogen Bio-pharmaceutical Tech. Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Nov 6, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase I, open-label, multi-center study to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary efficacy of CG-7321 capsules as monotherapy or in combination with fulvestrant or letrozole in subjects with advanced solid tumors. The study consists of: * Part Ia (Monotherapy): Dose escalation (accelerated titration followed by 3+3 design) from 2mg to 50mg twice daily (BID), plus dose expansion cohorts in advanced solid tumors including HR+/HER2- breast cancer, ovarian cancer, gastric cancer, and other tumor types. * Part Ib (Combination Therapy): Dose escalation of CG-7321 combined with fulvestrant or letrozole in HR+/HER2- advanced breast cancer.
Conditions
- Advanced Solid Tumors
- Breast Cancer
- Ovarian Cancer
- Gastric Cancer
- Other Solid Tumors
Interventions
CG-7321Drug
Novel oral cyclin-dependent kinase (CDK) inhibitor. Ia dose levels: 2mg, 6mg, 12mg, 20mg, 30mg, 40mg, 50mg BID. Ib dose levels: 30mg, 40mg, 50mg BID. 28-day cycle.
FulvestrantDrug
Selective estrogen receptor degrader (SERD). 500mg IM on Cycle 1 Day 1 and Day 15, then Day 1 of each subsequent cycle.
LetrozoleDrug
Aromatase inhibitor. 2.5mg orally once daily, continuous dosing.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Dose-Limiting Toxicities (DLTs)Time frame: DLT observation period [approximately 28 days]
- Maximum Tolerated Dose (MTD)Time frame: End of dose escalation phase [approximately 6-12 months]
- Recommended Phase 2 Dose (RP2D)Time frame: End of dose escalation phase [approximately 6-12 months]
- Adverse Events (AEs) and SAEsTime frame: From first dose to 30 days after last dose [up to approximately 2 years]
Locations
4 sites in 1 country. Site status is shown where the registry gives one.
Fujian Cancer Hospital
Fuzhou, Fujian, China · Recruiting
Zhongshan Hospital of Dalian University
Dalian, Liaoning, China · Recruiting
Fudan University Shanghai Cancer Center
Shanghai, Shanghai Municipality, China · Recruiting
West China Hospital, Sichuan University
Chengdu, Sichuan, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.